Procalcitonin as a Marker for the Length of Antibiotic Treatment in Peritonitis and Intra-abdominal Infections

Procalcitonin level used for determining length of antibiotic treatment in peritonitis and intra-abdominal infections. Hypothesis is that length of antibiotic use can be shortened by this method.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Secondary or Tertiary Peritonitis Neoplasm Metastasis Neoplasms Neoplastic Processes Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Hospital of Lausanne

Lausanne, 1011, Switzerland

About this study

Prospective randomized trial

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

More than 18 yo
Patient requiring surgery for peritonitis or intra-abdominal infection following: perforation, necrosis, previous operation...
Mannheim Peritonitis score > 14
SIRS present
Probability of survival > 72h
Informed consent by patient/relatives

Exclusion criteria

No SIRS
Long date corticoid treatment
Immunosuppression
Thyroid medullary carcinoma
Anaphylactic shock
Acute hepatic deficiency

Treatment and study plan

Primary outcomes

antibiotic treatment length, hospitalisation length without antibiotic, infection recurrence, antibiotic cost

Time frame: at one month and during hospital stay

Sponsors and collaborators

Lead sponsor

University of Lausanne Hospitals

Other

Registry information

Official study title

Etude Prospective Sur l'Impact de l'Utilisation de la Procalcitonine Dans l'évaluation de la Poursuite ou de l'arrêt du Traitement Antibiotique Empirique Lors de péritonites et d'Infections Intra-abdominales

Important dates

Study start: 2009
Primary completion: 2014
Study completion: 2014
First posted: Jul 2, 2010
Registry last updated: Dec 19, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed